Dawn C. Buse PhD
Clinical Professor of Neurology
Albert Einstein College of Medicine
New York City
PainRelief.com: What is the
background for this study?
Response: Sleep is essential in the regulation of a wide range of homeostatic
functions. Dysregulation of sleep process may be triggers for
migraine attacks and increase the risk of migraine disease
chronification. Migraine is comorbid with a range of medical,
neurologic, and psychiatric comorbidities that may exacerbate the disease,
complicate treatment, and reduce health-related quality of
life. These comorbidities include sleep disorders such as sleep
apnea, insomnia, circadian rhythm (i.e., sleep-wake) disorders, and sleep
The Chronic Migraine Epidemiology and Outcomes
(CaMEO) Study is a longitudinal study that used a series of web-based surveys
over 15 months to assess migraine symptoms, burden and patterns of healthcare
utilization among people in the US population. Validated
questionnaires were used to assess many comorbidities. Migraine can
be classified based on the number of headache days per month into episodic
migraine (<15 headache days/month) and chronic migraine (≥15 headache
In this cross-sectional analysis of data from the Chronic Migraine Epidemiology and Outcomes (CaMEO) Study, we assessed sleep apnea and poor sleep quality in a US population based sample of 12,810 people with migraine. Respondents were stratified by episodic (11,699) and chronic (1,111) migraine and by body mass index (BMI).
PainRelief.com Interview with:
Lars Jacob Stovner MD PhD
Professor of Neurology
Department of Neuromedicine and Movement Science
NTNU, Norwegian University of Science and Technology
Head of the Norwegian Advisory Unit on Headaches,
St. Olavs Hospital Trondheim, Norway
PainRelief.com: What is the background for this study? What are the main findings?
Response: The study focuses on prevalence and burden of migraine and tension-type headache in the Global Burden of Disease project from 2016.
Previous analyses has shown that migraine is the second most disabling disorder in terms of years lived with disability. This particular analysis shows that more than 1 billion people suffered from migraine in 2016 and 1.9 billion from tension-type headache, and it gives estimates each country and different world regions.
Headache is particularly burdensome in young and middle-aged women, but the impact is also quite marked also in men, children and elderly.
There is considerable variation between countries, but the burden is relatively stable over time (from 1990), and there is no obvious relation to the socioeconomic level of the country. Continue reading
PainRelief.com Interview with:
Gudarz Davar, M.D., Vice President
Neuroscience Platform Leader
Eli Lilly and Company
PainRelief.com: What is the background for this announcement? How big a problem is migraine in the US? Who is primarily affected?
Response: Migraine is a disabling, neurologic disease that affects more than 30 million American adults. According to the Medical Expenditures Panel Survey, the total unadjusted cost associated with migraine in the U.S. is estimated to be as high as $56 billion annually. People with migraine can miss out on significant moments in their lives—birthdays and anniversaries—and there remains an unmet need for treatment options that can help patients achieve significant reductions in the overall frequency of migraine attacks.
Emgality (galcanezumab-gnlm) was approved by the FDA on Thursday, September 27, for the preventive treatment of migraine in adults. Emgality is a humanized monoclonal antibody indicated for the preventive treatment of migraine in adults that binds to CGRP ligand and blocks its binding to the receptor, which is believed to play a role in migraine. It is offered as a self-administered, once-monthly subcutaneous injection. Emgality offers new hope to people living with migraine as one of the first medicines developed specifically for the prevention of migraine.
This study is systematic review and meta-analysis to evaluate the tolerability and efficacy of intranasal sumatriptan for the treatment of acute migraine attacks. Taste disturbance was a leading side effect.
Intranasal sumatriptan for acute migraine attacks: a systematic review and meta-analysis.
Menshawy A1,2,3, Ahmed H2,4,5, Ismail A1,2,6, Abushouk AI7,8,9, Ghanem E1,2, Pallanti R1,10, Negida A2,4,5.
Note: Content is Not intended as medical advice. Please consult your health care provider regarding your specific medical condition and questions.